Wednesday, August 26, 2026
ExploreSearch
Via News
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· January 1, 2026

Best CBD Gummies 2026 Consumer Report: Full Spectrum Formulations, Lab Testing Standards, and State Legal Requirements Examined in Consumer Wellness Category Analysis

View original at globenewswire.com
Best CBD Gummies 2026 Consumer Report: Full Spectrum Formulations, Lab Testing Standards, and State Legal Requirements Examined in Consumer Wellness Category Analysis LOS ANGELES, CA, Jan…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Entourage Effect theory that cannabinoids work differently together versus isolated is not definitively established

    80% confidence

  • No full spectrum CBD product can guarantee drug test outcomes

    80% confidence

  • Existing regulatory frameworks for foods and dietary supplements deemed not appropriate for cannabidiol

    80% confidence

  • No CBD products evaluated by FDA for safety or efficacy as supplements

    80% confidence

  • No evidence of recreational use of CBD or any public health-related problems associated with use of pure CBD

    80% confidence

  • CBD is generally well tolerated with a good safety profile

    80% confidence

  • Product uses cold-pressed, unrefined CBD extraction with CO2 extraction technology and triple filtration technology for THC processing

    80% confidence
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
AI Leadership Exodus Rattles Investor Confidence Amid Capex Boom
High-profile departures at top AI labs — Brad Lightcap's exit from OpenAI and an unnamed researcher's departure from Alphabet/Google that triggered a share-price drop — are surfacing talent retention as a market risk factor even as hyperscalers pour record capital into AI infrastructure. The reaction shows investors treating key-person risk at frontier AI labs as material to valuation, a new fragility layered onto an otherwise bullish AI-driven capex cycle.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Broadcom Inc.
Both facts report EPS for Broadcom Inc. for the same fiscal period (Q1 2026) observed on the same date (2026-02-01). However, they report conflicting values: 1.5 USD per share vs 2.05 USD per share. This is a 37% difference for the identical metric and time period, not a value change over time.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,978
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,978 facts checked against source5,251 source documents archived
Query this data → isubstrate.com
Best CBD Gummies 2026 Consumer Report: Full Spectrum Formulations, Lab Testing Standards, and State Legal Requirements Examined in Consumer Wellness Category Analysis — Source | Via News | ViaNews Market